Magdent
Investment ID: Catapult Crown 2
 copy (1) copy.jpg)
Secure your allocation in Magdent today!
Investment Overview
Investment Overview
The $4B dental implantation industry suffers from three main challenges[1]:
- A long healing process, which ranges from 3-6 months, and up to 9 months in cases of bone grafts.
- Failure with high-risk patients, mostly due to poor bone quality.
- Peri-implant Mucositis / Peri-implantitis which appears in around 34% of cases.
Magdent’s groundbreaking Miniaturized Electromagnetic Device (MED) utilizes Pulsed Electro-Magnetic Fields (PEMF) which offers a potential solution to all three of these challenges. The MED can be inserted into up to 85% of implant brands and models and has the potential to (i) accelerate bone growth (osseogenesis) and thus reduce the healing period from 3-6 months to 1-2 months; (ii) improve implantation success chances in high-risk patients by improving bone quality, increasing bone-to-implant contact and the trabecular bone volume density; and (iii) stimulate bone growth even for patients suffering from peri-implantitis.
Initial clinical trial results conducted at the Rambam Health Care Campus in Israel (Completed Q4 2022) have shown that Magdent’s MED stimulates bone growth for patients suffering from peri-implantitis, which may provide the first-ever treatment for peri-implantitis. After completing additional clinical trial studies, Magdent will publish its results and initiate its efforts to receive FDA approval and a CE Mark for this peri-implantitis feature of its product, which is currently available for the osseogenesis feature.
Funding Target
$ 4,000,000
Website
Webinars And Videos
